Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00110799 · ClinicalTrials.gov registry record · Phase 2
SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C
A Phase 2 study of Hepatitis C and Hepatitis C, Chronic, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 20
- Study locations
NCT00110799: Completed Phase 2 study of Hepatitis C and Hepatitis C, Chronic, sponsored by GlaxoSmithKline.
NCT00110799 is a Phase 2 study of Hepatitis C and Hepatitis C, Chronic that has completed, run by GlaxoSmithKline. The registered enrollment target is 75 participants, below the 1,889-participant average among 106 other Hepatitis C trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00110799, a Phase 2 study of Hepatitis C and Hepatitis C, Chronic, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 20
- Study locations
Study Summary
SB497115 is an oral agent which activates the thrombopoietin receptor and increases platelet counts in healthy volunteers. This study is examining several different doses of SB497115 as a treatment for patients with chronic hepatitis C-related thrombocytopenia who are potential candidates for antiviral treatment with pegylated interferon and ribavirin. The study will be conducted in two phases, Parts 1 and 2. In Part 1, study subjects will be randomized to 4 weeks of SB-497115-GR or placebo administered daily without antiviral therapy. Subjects who successfully complete Part 1 (platelet count 70,000/µL for Pegasys and platelet count 100,000/µL for PEG-Intron) will then proceed to Part 2. In Part 2, subjects will receive an additional 8 weeks of SB-497115-GR or placebo administered daily with antiviral therapy.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG SB497115
Study Locations (20)
Other
- GSK Investigational Site - Clermont Ferrand Cédex 1
- GSK Investigational Site - Clichy
- GSK Investigational Site - Lyon
- GSK Investigational Site - Lyon
- GSK Investigational Site - Marseille
- GSK Investigational Site - Nice
- GSK Investigational Site - Paris
- GSK Investigational Site - Pessac
- GSK Investigational Site - Vandœuvre-lès-Nancy
Virginia
- GSK Investigational Site - Fairfax
- GSK Investigational Site - Richmond
Colorado
- GSK Investigational Site - Denver
Massachusetts
- GSK Investigational Site - Boston
Michigan
- GSK Investigational Site - Detroit
Missouri
- GSK Investigational Site - St Louis
New York
- GSK Investigational Site - New York
North Carolina
- GSK Investigational Site - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2005-04 |
| Est. Completion | 2006-11 |
| Phase | Phase 2 |
What the finished NCT00110799 record still lists
NCT00110799 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 1,889-participant average among 106 other Hepatitis C trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00110799 names 20 study sites across 11 states, led by Other, Virginia, Colorado.
Frequently Asked Questions
What is clinical trial NCT00110799 about?
NCT00110799 is a clinical study titled "SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C". SB497115 is an oral agent which activates the thrombopoietin receptor and increases platelet counts in healthy volunteers. This study is examining several different doses of SB497115 as a treatment for patients with chronic hepatitis C-related thrombocytopenia who are potential candidates for antivi...
What is the current status of trial NCT00110799?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2005-04. Estimated completion is 2006-11.
What conditions does trial NCT00110799 study?
This clinical trial studies the following conditions: Hepatitis C, Hepatitis C, Chronic, Thrombocytopenia.
What interventions are being tested in trial NCT00110799?
The interventions under investigation include: Placebo (OTHER), SB497115 (DRUG).
Who is sponsoring clinical trial NCT00110799?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00110799 being conducted?
This trial has 20 study locations across Colorado, Massachusetts, Michigan, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00110799's enrollment target sits among peer trials
75 62nd of 106 higher than 45 of 106 other Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients
ACTIVE NOT RECRUITING · Phase 2
-
Expanding the Pool in Orthotopic Heart Transplantation
ACTIVE NOT RECRUITING · Phase 2
-
The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients
COMPLETED · Phase 2
-
Dose Finding Trial of Rosuvastatin and Atorvastatin Versus Hepatitis C
COMPLETED · Phase 2
-
A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C
COMPLETED · Phase 2
-
Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia